Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 101–103.

https://doi.org/10.1182/blood-2022-158694

Published: 2022

Journal Articles

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Joseph Saad, Samuli Eldfors, Vilma Ikonen, Bjørn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 1033–1035.

https://doi.org/10.1182/blood-2022-163242

Published: 2022

Journal Articles

ATR/CHK1/WEE1 Dependency in SRSF2 -Mutated MDS/AML

Samuli Eldfors, Sumit Rai, Vineet Sharma, Angelique N Gilbert, Kimmo Porkka, Timothy A. Graubert

Blood (2021) 138 (Supplement 1): 3661.

https://doi.org/10.1182/blood-2021-147960

Published: 2021

Journal Articles

Predictive Response Biomarkers for BET Inhibitors in AML

Joseph J Saad, MSc, BSc, Juho Miettinen, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Samuli Eldfors, PhD, Mika Kontro, MD, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Jing Tang, PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2018-99-118363

Published: 2018

Journal Articles

A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines

Blood (2018) 132 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2018-99-114593

Published: 2018

Journal Articles

Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency

Paula Savola, MD, Timi Martelius, MD PhD, Matti Kankainen, PhD, Yrjö Koski, BTech, Samuli Eldfors, PhD, Jani Huuhtanen, BMed, Tiina Kelkka, PhD, Sofie Lundgren, BMed, Pekka Ellonen, BSc, Panu Kovanen, MD PhD, Soili Kytölä, PhD, Mikko Seppänen, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 515.

https://doi.org/10.1182/blood-2018-99-110757

Published: 2018

Journal Articles

Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells

Hanna Rajala, MD PhD, Paula Savola, MD, Sofie Lundgren, BMed, Samuli Eldfors, PhD, Tiina Kelkka, PhD, Freja Ebeling, MD PhD, Satu Mustjoki, MDPhD

Blood (2018) 132 (Supplement 1): 131.

https://doi.org/10.1182/blood-2018-99-113373

Published: 2018

Journal Articles

Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes

Sofie Lundgren, Mikko Keränen, MD PhD, Kari Nousiainen, Samuli Eldfors, Sari Hannula, Tiina Hannunen, Pekka Ellonen, Gunilla Walldin, Michael Clemente, Freja Ebeling, MD PhD, Hanna Rajala, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP, Harri Lähdesmäki, PhD, Eva Hellstrom-Lindberg, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 1169.

https://doi.org/10.1182/blood.V130.Suppl_1.1169.1169

Published: 2017

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)

Giljun Park, PhD, Daehong Kim, Sofie Lundgren, Rajiv K Khajuria, Ana M Hurtado, Cecilia Muñoz-Calleja, Dra, Laura Cardeñoso, Samuli Eldfors, Pekka Ellonen, Sari Hannula, Oscar Brück, Anna Kreutzman, PhD, Andres Jerez, Maija Itälä-Remes, MD PhD, Mikko A Keränen, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 4487.

https://doi.org/10.1182/blood.V130.Suppl_1.4487.4487

Published: 2017

Journal Articles

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Muntasir M Majumder, MSc, BPharm, David Tamborero, PhD, Pekka Anttila, Raija Helena Silvennoinen, MD, Samuli Eldfors, MSc, Juha Lievonen, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Esa Jantunen, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 4412.

https://doi.org/10.1182/blood.V130.Suppl_1.4412.4412

Published: 2017

Journal Articles

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, Bhagwan Yadav, PhD, Soili Kytölä, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 250.

https://doi.org/10.1182/blood.V130.Suppl_1.250.250

Published: 2017

Journal Articles

Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments

Susanna Teppo, MSc, Juha Mehtonen, MSc, Samuli Eldfors, MSc, Caroline A Heckman, PhD, Markus Müschen, MD PhD, Merja Heinäniemi, PhD, Olli Lohi

Blood (2016) 128 (22): 4077.

https://doi.org/10.1182/blood.V128.22.4077.4077

Published: 2016

Journal Articles

Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies

Blood (2016) 128 (22): 2921.

https://doi.org/10.1182/blood.V128.22.2921.2921

Published: 2016

Journal Articles

Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, MSc, Soili Kytölä, PhD, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 1924.

https://doi.org/10.1182/blood.V128.22.1924.1924

Published: 2016

Journal Articles

DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors

Muntasir M Majumder, MSc, MPharm, David Tamborero, PhD, Pekka Anttila, MD, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Ashwini Kumar, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Esa Jantunen, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2016) 128 (22): 198.

https://doi.org/10.1182/blood.V128.22.198.198

Published: 2016

Journal Articles

High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia

Blood (2016) 128 (20): 2465–2468.

https://doi.org/10.1182/blood-2016-06-724856

Published: 2016

Includes: Supplemental data

Journal Articles

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Mika Kontro, MD, Samuli Eldfors, MSc, Muntasir Mamun Majumder, MSc,MPharm, Alun Parsons, MSc, Tea Pemovska, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD

Blood (2015) 126 (23): 2462.

https://doi.org/10.1182/blood.V126.23.2462.2462

Published: 2015

Journal Articles

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

Muntasir Mamun Majumder, MSc,MPharm, Raija Silvennoinen, MD, Pekka Anttila, MD, David Tamborero, PhD, Samuli Eldfors, MSc, Juha Lievonen, MD, Riikka J Karjalainen, Heikki Kuusanmäki, MSc, Alun Parsons, Minna Suvela, Kimmo Porkka, MD PhD, Caroline Heckman

Blood (2015) 126 (23): 3006.

https://doi.org/10.1182/blood.V126.23.3006.3006

Published: 2015

NARROW

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

ATR/CHK1/WEE1 Dependency in SRSF2 -Mutated MDS/AML

Predictive Response Biomarkers for BET Inhibitors in AML

A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines

Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency

Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells

Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments

Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies

Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia

DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors

High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only